Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Higher enterolactone levels linked to lower risk of ERalpha-negative cancer
March 10th, 2005
A study from Denmark determined that higher plasma concentrations of the phytoestrogen enterolactone are associated with lower risk of developing estrogen receptor-negative breast cancer. "The phytoestrogen enterolactone has been hypothesized to prevent breast cancer. Because one of the biological effects of enterolactone is probably estrogenic, it is possible that the preventive effect on breast cancer differs with the estrogen receptor (ER) alpha status of the tumor," wrote A. Olsen and colleagues with the Danish Cancer Society, Institute of Cancer Epidemiology. Their study was designed to determine if "high plasma levels of enterolactone are...
Source: Women's Health Weekly (2005-03-10)
|
